Matrix metalloproteinases and hypertension: A link between left ventricular hypertrophy and diastolic dysfunction?

Tohoku Journal of Experimental Medicine

Volumn 208, Issue 2, 2006, Pages 93-97

  Karthikeyan, V J ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGENASE 3; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 17; NEUTROPHIL COLLAGENASE; STATIN; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTERY DISEASE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLLAGEN METABOLISM; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; EDITORIAL; ENDOTHELIUM LESION; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; INFLAMMATION; MATERNAL HYPERTENSION; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

BLOOD PRESSURE; DIASTOLE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR DYSFUNCTION;

EID: 31744450088     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.208.93     Document Type: Editorial

References (21)

1. Boos, C.J. & Lip, G.Y.H. (2005) Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a relationship between inflammation and hypertension? J. Hum. Hypertens., 19, 511-513.
2. Lindsay, M.M., Maxwell, P. & Dunn, F.G. (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension, 40, 136-141.
3. Li-Saw-Hee, F.L., Edmunds, E., Blann, A.D., Beevers, D.G. & Lip, G.Y.H. (2000) Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int. J. Cardiol., 75, 43-47.
4. Malemud, C.J. (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci., 11, 1696-1701.
5. McEniery, C.M. & Wilkinson, I.B. (2005) Large artery stiffness and inflammation. J. Hum. Hypertens., 19, 507-509.
6. Noji, Y., Shimizu, M., Ino, H., Higashikata, T., Yamaguchi, M., Nohara, A., Horita, T., Shimizu, K., Ito, Y., Matsuda, T., Namura, M. & Mabuchi, H. (2004) Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction. Circ. J., 68, 355-360.
7. Saglam, M., Karakaya, O., Esen, A.M., Barutcu, I., Dogan, S., Karavelioglu, Y., Karapinar, H., Akgun, T., Esen, O., Ozdemir, N., Turkmen, S. & Kaymaz, C. (2006) Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku. J. Exp. Med., 208, 117-122.
8. Schram, M.T., van Ittersum, F.J., Spoelstra-de Man, A., van Dijk, R.A., Schalkwijk, C.G., Ijzerman, R.G., Twisk, J.W. & Stehouwer, C.D. (2005) Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial. J. Hum. Hypertens., 19, 429-437.
9. Soejima, H., Ogawa, H., Sakamoto, T., Miyamoto, S., Kajiwara, I., Kojima, S., Hokamaki, J., Sugiyama, S., Yoshimura, M., Suefuji, H., Miyao, Y., Fujimoto, K., Miyagi, H. & Kishikawa, H. (2003) Increased serum matrix metalloproteinase-1 concentration predicts advanced left ventricular remodeling in patients with acute myocardial infarction. Circ. J., 67, 301-304.
10. Sundstrom, J., Evans, J.C., Benjamin, E.J., Levy, D., Larson, M.G., Sawyer, D.B., Siwik, D.A., Colucci, W.S., Wilson, P.W. & Vasan, R.S. (2004) Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J., 25, 1509-1516.
11. Tayebjee, M.H., MacFadyen, R.J. & Lip, G.Y.H. (2003) Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J. Hypertens., 21, 2211-2218.
12. Tayebjee, M.H., Nadar, S.K., MacFadyen, R.J. & Lip, G.Y.H. (2004) Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: Relationship to tissue Doppler indices of diastolic relaxation. Am. J. Hypertens., 17, 770-774.
13. Tayebjee, M.H., Karalis, I., Nadar, S.K., Beevers, D.G., MacFadyen, R.J. & Lip, G.Y.H. (2005a) Circulating Matrix Metalloproteinase-9 and Tissue Inhibitors of Metalloproteinases-1 and -2 levels in Gestational Hypertension. Am. J. Hypertens., 18, 325-329.
14. Tayebjee, M.H., Lim, H.S., Nadar, S., MacFadyen, R.J. & Lip, G.Y.H. (2005b) Tissue inhibitor of metalloproteinase-I is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertension. Eur. J. Clin. Invest., 35, 8-12.
15. Tayebjee, M.H., Lip, G.Y.H. & MacFadyen, R.J. (2005c) Matrix Metalloproteinases in Coronary Artery Disease: Clinical and Therapeutic Implications and Pathological Significance. Curr. Med. Chem., 12, 763-771.
16. Tayebjee, M.H., Lip, G.Y.H., Tan, K.T., Patel, J.V., Hughes, E.A. & MacFadyen, R.J. (2005d) Plasma Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-2 and CD40 Ligand levels in Patients with Stable Coronary Disease. Am. J. Cardiol., 96, 339-345.
17. Tayebjee, M.H., Tan, K.T., MacFadyen, R.J. & Lip, G.Y.H. (2005e) Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J. Int. Med., 257, 110-116.
18. Timms, P.M., Wright, A., Maxwell, P., Campbell, S., Dawnay, A.B. & Srikanthan, V. (2002) Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am. J. Hypertens., 15, 269-272.
19. Varughese, G.I. & Lip, G.Y.H. (2005) Hypertension in patients with type-II diabetes: relation to urinary albumin excretion, endothelial function and inflammation. J. Hum. Hypertens., 19, 421-424.
20. Williams, B., Poulter, N.R., Brown, M.J., Davis, M., McInnes, G.T., Potter, J.F., Sever, P.S., McG, Thom, S. & British Hypertension Society (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J. Hum. Hypertens., 18, 139-185.
21. Zervoudaki, A., Economou, E., Stefanadis, C., Pitsavos, C., Tsioufis, K., Aggeli, C., Vasiliadou, K., Toutouza, M. & Toutouzas, P. (2003) Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J. Hum. Hypertens., 17, 119-124.